Indication intelligence, analysis and sector perception

RegMed Investors’ (RMI) Earnings: dates of releases and more results

August 16, 2022 11:38am

Upcoming Q2 earnings announcements … 34 of 35 reported so far

Added: Brainstorm Cell Therapeutics (BCLI) and Homology Medicine (FIXX) on Monday, 8/15

Results are listed below ...

Release Results:

Ultragenyx (RARE) reported a net loss of -$158.2 M or -$2.26 per share with $706.1 M in cash

Alnylam Pharmaceuticals (ALNY) reported a net loss of -$227.4 M or -$2.29 per share with 575.5 M in cash

Sage therapeutics (SAGE) reported a net loss of -$126.3 M or -$2.13 per share with $1.13 B in cash and a "runway" until 2025

Vericel (VCEL) reported a net loss of -$9 M or -$0.19 per share with $131M in cash and a runway to 2025.

Editas Medicine (EDIT) reported a quarterly loss of -$53.5 M or -$0.78 per share with a cash position of $527.6 m and a runway until 2024; shares have lost about 37.9% since the beginning of the year.

MiMedx (MDXG) reported a net loss of -$10.9 M or -$0.11 with $72.5 M in cash and a runway until 2024.

AxoGen (AXGN) reported a new loss of -$2.6 M or -$0.06 per share with $64.3 M in cash and a runway until 2024.

Fate Therapeutics (FATE) reported a new loss of -$76.1 m or -$0.79 per share with $580.8 M in cash and a runway until 2025

Regenxbio (RGNX) reported a net loss of -$68.2 M or -$1.58 per share with a cash position of $682 M and a runway until 2025

MiMedx (MDXG) reported a net loss of -$10.9 M or -$0.11 with $72.5 M in cash and a runway until 2024

Sage Therapeutics (SAGE) reported a net loss of -$126.3 M or -$2.13 per share with $1.3 b in cash and a runway until 2025

Intellia Therapeutics (NTLA) reported a net loss of -$100.7 M or -$1.33 per share and a cash position of $906.9 M (an ATM of -$38.9 M and a draw of -$14.3 M from employee stock plans) with a runway until 2025.

Sangamo Therapeutics (SGMO) reported a net loss of -$43.2 m or -$0.29 and a cash position of $363.7 M with a runway until 2025.

Voyager Therapeutics (VYGR) reported a new loss of -$19.1 M or -$0.50 per share and a cash position of 148.1 M with a runway until 2024.

Biostage (BSTG) reported a net loss of -$1.3 M or -0.12 per share and a cash position of $4.6M with a runway until Q2/2023 and preparing a stock reverse to execute a financing by non-U.S. Chinese investors.

bluebird bio (BLUE) reported a net loss of -$100.1 M or -$1.36 per share and a cash position of $218 M (used $8 M from a $24.7M ATM) with a runway until 2024 but, exploring alternative financing

Cellectis SA (CLLS) reporteda newt loss of -$18.9 M or -$0.36 per share and a cash position of $135 M with a runway until 2024

CRISPR Therapeutics (CRSP) reported a newt loss of -$185 M or -$2.40 per share and a cash position of $2.073.7 B with a runway until 2025

uniQure NV (QURE) reported a net loss of -$39.1 M or -0.84 per share and a cash position of $500.5 M with a runway until 1H/2025

Verastem Oncology (VSTM) reported a net loss of -$22 M or a -$0.12 per share and a cash position of $94.3 M with a runway until 2025 (with credit facility)

Precigen (PGEN) reported a net loss of -$26.1 M or -0.13 and a cash position of $132.8 M (note: selling TransOva for $170 M to close in Q3) with a runway until 2024

Chinook Therapeutics (KDNY) reported a net loss of -$37.6 M or -0.61 per share and a cash position of $405.2 M with a runway until Q4/23

Agenus (AGEN) reported a net loss of -$49.2 M or -0.17 and a cash position of $238 M (plus $25 M in 2H/22 from Shinqrix) with a runway until 2024

Ionis Pharmaceuticals (IONS) reported a new loss of -$105 m or -0.74 per share and a cash position of $2 B with a runway until 2025

Avrobio (AVRO) reported a net loss of -$28.05 m or -0.64 per share and a cash position of $132.4 M with a runway until Q1/2024

Verve therapeutics (VERV) reported a net loss of -$40.9 m or -0.84 and a cash position of $293.6 M with a runway until 2h/25

Beam Therapeutics (BEAM) reported a new loss of -$72 M or -$1.02 per share with a cash position of $1.2 B with a runway until 2025

BioLife Solutions (BLFS) reprtedd a new loss of -$72.6 M or -$1.71 per share and a cash position of $46.6 M with a runway until 2024

Caribou Biosciences (CRBU) reported a net loss of -$26.7 M or -$0.44 per share and a cash position of $366.1 M with a runway until 2025

Solid Biosciences (SLDB) reported a net loss of -$25.1 M or -$0.22 per share and a cash position of $169.2 M with a runway until Q2/2024

Adverum Biotechnologies (ADVM) reported a net loss of -$43.8 M or -$0.44 per share and a cash position of $235.8 M with a runway until Q1/2024

Bellicum Pharmaceuticals (BLCM) reported a net loss of -$4 M or -0.13 per share and a cash position of $34.7 M with a runway until early 2024

Brainstorm Cell Therapeutics (BCLI) reported a net loss of -$7 M or -0.19 per share and a cash position of $12.2 M with a runway until Q4/2022

Homology Medicine (FIXX) reported a net loss of -$29.1 M or -$0.51 per share and a cash position of $225.5 M with a runway until Q4/2024

We always need a … villain and they are always multiplying – low volume as “Earnings’ season continues with a topsy-turvy share pricing which I believe will get WORSE, investors NEED to focus on LPS (loss-per-share), collaboration revenues and cash positions i.e., runways”.

T consider investment which ... CEOs are investing in their "employed" companies of which WE INVESTORS OWN; SG&A has become much too much strpping cash to unsuitable levels!!

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.